Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
13. lappuse
... effective for use in self - medication as directed in proposed labeling . A proposal to exempt a drug from the prescription - dispensing re- quirements of section 503 ( b ) ( 1 ) ( C ) of the act may be initiated by the Commis- sioner ...
... effective for use in self - medication as directed in proposed labeling . A proposal to exempt a drug from the prescription - dispensing re- quirements of section 503 ( b ) ( 1 ) ( C ) of the act may be initiated by the Commis- sioner ...
20. lappuse
... effective for its intended use ( s ) . After approval , the applicant is required to establish and maintain records ... effectiveness of long - term use of such drugs , extensive animal and clini- cal tests are required as a condition of ...
... effective for its intended use ( s ) . After approval , the applicant is required to establish and maintain records ... effectiveness of long - term use of such drugs , extensive animal and clini- cal tests are required as a condition of ...
23. lappuse
... EFFECTIVE DATE NOTE : At 62 FR 52249 , Oct. 7 , 1997 , § 310.305 was amended by adding a new sentence at the end of ... effective Apr. 6 , 1998. For the convenience of the user , the su- perseded text is set forth as follows : $ 310.305 ...
... EFFECTIVE DATE NOTE : At 62 FR 52249 , Oct. 7 , 1997 , § 310.305 was amended by adding a new sentence at the end of ... effective Apr. 6 , 1998. For the convenience of the user , the su- perseded text is set forth as follows : $ 310.305 ...
27. lappuse
... effectively removed from the body by dialysis , exchange transfusion , or during cardiopulmonary bypass , presumably ... effective in " high output " ( bronchopulmonary insuffi- ciency , infection , hyperthyroidism ) heart failure ...
... effectively removed from the body by dialysis , exchange transfusion , or during cardiopulmonary bypass , presumably ... effective in " high output " ( bronchopulmonary insuffi- ciency , infection , hyperthyroidism ) heart failure ...
33. lappuse
... effective use of oral contraceptive drug products requires that patients be fully informed of the benefits and the ... effectiveness of oral contraceptives in preventing preg- nancy , the contraindications to the drug's use , and a ...
... effective use of oral contraceptive drug products requires that patients be fully informed of the benefits and the ... effectiveness of oral contraceptives in preventing preg- nancy , the contraindications to the drug's use , and a ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning